S. Chiara

Intraperitoneal versus Intravenous Cisplatin in Combination with Intravenous Cyclophosphamide and Epidoxorubicin in Optimally Cytoreduced Advanced Epithelial Ovarian Cancer: A Randomized Trial of the Gruppo Oncologico Nord-Ovest

Angiolo Gadducci, F Carnino, S. Chiara et al. · Gynecologic Oncology · 2000 · 142 citations · Full text

Medicine, Gynecology, Oncology +16

High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest.

PierFranco Conte, Milena Bruzzone, F Carnino et al. · Journal of Clinical Oncology · 1996 · 90 citations · Full text

Medicine, Oncology, Pharmacology +17

FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials

Chiara Cremolini, Fotios Loupakis, Gianluca Masi et al. · Annals of Oncology · 2016 · 58 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look

Milena Bruzzone, Lazzaro Repetto, S. Chiara et al. · Gynecologic Oncology · 1990 · 55 citations · Full text

Medicine, Gynecology, Oncology +17

The triplet combination of irinotecan, oxaliplatin and 5FU/LV (FOLFOXIRI) vs the doublet of irinotecan and 5FU/LV (FOLFIRI) as first-line treatment of metastatic colorectal cancer (MCRC): Results of a randomized phase III trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.)

Alfredo Falcone, Gianluca Masi, I. Brunetti et al. · Journal of Clinical Oncology · 2006 · 25 citations

Medicine, Oncology, Pharmacology +16